MC
BMRN icon

Machina Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Machina Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,684
Closed -$242K – 284
2024
Q4 		$242K Sell
3,684
-3,865
-51% -$259K 0.1% 241
2024
Q3 		$531K Buy
7,549
+1,832
+32% +$153K 0.21% 166
2024
Q2 		$471K Buy
5,717
+589
+11% +$49K 0.21% 180
2024
Q1 		$448K Buy
+5,128
New +$459K 0.24% 163
2023
Q3 		– Sell
-7,928
Closed -$687K – 269
2023
Q2 		$687K Buy
+7,928
New +$746K 0.39% 102
2022
Q4 		– Sell
-2,668
Closed -$226K – 151
2022
Q3 		$226K Buy
+2,668
New +$238K 0.48% 110
2022
Q2 		– Sell
-3,017
Closed -$233K – 128
2022
Q1 		$233K Buy
+3,017
New +$252K 0.51% 94

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Machina Capital's BMRN Position: Q1 2025 in Review

Machina Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 3,684 shares — an estimated $242K sold.

Machina Capital first reported a position in BMRN in Q1 2022 and held it in 7 quarters. The position peaked at $687K in Q2 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Machina Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Machina Capital sold 3,684 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $242K.
  • Machina Capital first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 7 quarters.
  • Machina Capital's BioMarin Pharmaceuticals position peaked at $687K in Q2 2023.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Machina Capital's 13F filing for Q1 2025, filed 6 May 2025.